

Gastric Amyloidosis Causing Nonvariceal Upper Gastrointestinal Bleeding

Sridhar Sundaram, MD, DM¹, and Raosaheb Rathod, MD²

¹Department of Gastroenterology, Seth GS Medical College and KEM Hospital, Mumbai, India

²Department of Digestive Diseases and Clinical Nutrition, Tata Memorial Hospital, Mumbai, India

CASE REPORT

A 59-year-old man, diagnosed with relapsed multiple myeloma, admitted currently in the intensive care unit with respiratory distress, acute kidney injury, and hypercalcemia, was referred for evaluation of upper gastrointestinal (GI) bleed. The patient was on mechanical ventilation with fresh blood aspirated using the Ryles tube. On investigation, hemoglobin was 7.6 g/dL and platelets were 63,000/mm³ with international normalized ratio 1.3. Bedside upper GI endoscopy showed diffuse erythema with thickening and nodularity involving the entire stomach, without any ulceration or active bleeding (Figure 1). Biopsies were taken from the stomach for evaluation. There was suspicion of fungal pneumonia on thorax computed tomography. Differential diagnoses included infective gastropathy and gastric involvement by amyloidosis. The




Figure 1. Thickened erythematous mucosa with nodularity in the body of the stomach.

patient was continued on pantoprazole, and antifungal antibiotics were added. Histopathological examination showed submucosal deposits of extracellular hyaline-like material around blood vessels, which is indicative of amyloid deposits (Figure 2). Congo red staining revealed an apple green refringence under polarized microscopy. Despite the supportive measures, the patient's condition deteriorated, and he eventually died.




Figure 2. Biopsy from the stomach shows the presence of perivascular eosinophilic deposits of amorphous material suggestive of amyloid.

Amyloidosis is a condition of extracellular fibrillar protein deposition, commonly associated with tissue injury and dysfunction.¹ GI involvement is uncommon in patients with amyloidosis, with a reported risk of only about 3%. Among patients with GI involvement, 79% have underlying systemic amyloidosis and 21% have only GI amyloidosis without evident plasma cell dyscrasia or extraintestinal involvement.² In the reported series, weight loss (45%), GI bleeding (36%), and heartburn (33%) were the most common symptoms of GI amyloid.³ Menke et al reported GI involvement in 8% of patients with systemic amyloidosis with 1% having symptomatic gastric involvement.⁴ Endoscopic findings in patients with gastric amyloidosis include submucosal tumors, polyps, thickened gastric folds, loss of rugal folds, antral narrowing, erythema, ulcerations, and erosions. Submucosal hematomas are often seen in patients who present with bleeding.⁵ Torrential bleeding can occur when the submucosal hematoma ruptures. Common sites of amyloid infiltration are the second part of the duodenum, stomach, colorectum, and esophagus.⁶ Congo red stains are recommended for patients with unexplained weight loss, bleeding, abdominal pain, or early satiety associated with a monoclonal gammopathy.

Currently, no treatment guidelines exist for endoscopic therapy for bleeding from gastric amyloidosis. Also, endoscopic therapy is largely ineffective in this setting. Amyloidosis of the stomach should be considered in patients with nonvariceal bleed and gastroparesis in the background of systemic amyloidosis. In addition, rarely despite the absence of systemic amyloidosis, amyloid deposits may be seen in the gastrointestinal tract. Hence, high index of suspicion is required for identification of this disorder.

DISCLOSURES

Author contributions: Both authors helped in patient management. S. Sundaram drafted the manuscript and is the article guarantor.

Financial disclosure: None to report.

Informed consent was obtained for this case report.

Received November 29, 2018; Accepted February 28, 2019

REFERENCES

1. Gillmore JD, Hawkins PN. Pathophysiology and treatment of systemic amyloidosis. *Nat Rev Nephrol*. 2013;9:574–86.
2. Cowan AJ, Skinner M, Seldin DC, et al. Amyloidosis of the gastrointestinal tract: A 13-year, single-center, referral experience. *Haematologica*. 2013; 98(1):141–6.
3. Singh K, Chapalamadugu P, Malet P. Upper gastrointestinal bleeding due to amyloidosis in a patient with multiple myeloma. *Clin Gastroenterol Hepatol*. 2016;14(11):A22–3.
4. Menke DM, Kyle RA, Fleming CR, Wolfe JT III, Kurtin PJ, Oldenburg WA. Symptomatic gastric amyloidosis in patients with primary systemic amyloidosis. *Mayo Clinic Proc*. 1993;68(8):763–7.
5. James DG, Zuckerman GR, Sayuk GS, Wang HL, Prakash C. Clinical recognition of AI type amyloidosis of the luminal gastrointestinal tract. *Clin Gastroenterol Hepatol*. 2007;5(5):582–8.
6. Tada S, Iida M, Iwashita A, et al. Endoscopic and biopsy findings of the upper digestive tract in patients with amyloidosis. *Gastrointest Endosc*. 1990;36(1):10–4.

Copyright: © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.